Paul Sekhri, eGenesis CEO
George Church spinoff swallows a key manufacturing partner as it preps CRISPR-edited pig organs for animal testing
Researching, cloning and breeding gene-edited pigs are core to eGenesis’ audacious mission to grow organs that can be xenotransplanted into humans. But perhaps unsurprisingly, little of that actually happens at its Cambridge, MA labs.
Rather, the biotech works with external parties for that part of the R&D and manufacturing work. As eGenesis approaches a final version of the gene-edited organs that it will test in animals, it’s acquiring one of those partners and integrating it as a subsidiary.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
